Nicola Hardwick, Ph.D.

Nicola Hardwick, Ph.D.

  • Regulatory Affairs Specialist I, Department of Experimental Therapeutics

Nicola Hardwick, Ph.D.

Research Focus :
  • Immunotherapy for cancer, including whole cell tumor vaccines, peptides, viral vectors and dendritic cells
  • Extensive experience with preclinical and clinical research
  • 2015-present, Regulatory Affairs Specialist I, Department of Experimental Therapeutics, City of Hope, Duarte, CA
  • 2014-2015, Staff Scientist, Department of Experimental Therapeutics, City of Hope, Duarte, CA
  • 2011-2014, Postdoctoral Research Fellow, Division of Translational Vaccine Research, Beckman Research Institute, City of Hope, Duarte, CA
  • 2008-2011, Postdoctoral Research Assistant, University College London, Department of Infection and Immunity, London, United Kingdom
  • 2000-2008, Research Assistant, Kings College London, Department of Molecular Medicine, London, United Kingdom
  • 1999-2000, Research Assistant, Imperial College London, Department of Biochemistry, London, United Kingdom
  • 1991-1996, Medical Laboratory Scientific Officer, Brighton General Hospital, Pathology Department, London, United Kingdom
  • 2008, Kings College London, London, United Kingdom, Ph.D., Cancer Studies
  • 1999, University College London, London, United Kingdom,  M.Phil., Immunology
  • 1996, University of Brighton, Brighton, United Kingdom, B.Sc. with Honors, Biomedical Sciences
  • Hardwick N, Frankel PH, Cristea M. New Approaches for Immune Directed Treatment for Ovarian Cancer. Curr Treat Options Oncol. 2016, 17(3):14. doi: 10.1007/s11864-016-0389-1. PMID: 26942589
  • Hofmann S, Mead A, Malinovskis A, Hardwick NR, Guinn BA. Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunol Immunother. 2015, 64(11):1357-67. doi: 10.1007/s00262-015-1762-9. Epub 2015 Oct 5. Review. PMID: 26438084
  • Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology. 2014, 3(10):e958949. PMID: 25941580
  • Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res. 2014, 20(17):4459-70. doi: 10.1158/1078-0432.CCR-13-3361. PMID: 24987057
  • Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti G, Stevenson F, Guinn BA. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun. 2013, 13:16. PMID: 23882161
  • Hardwick N, Ledermann JA, Aitkens E, Chain B. Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease. Cancer Immunol Immunother. 2012 , 61(11):1929-39. doi: 10.1007/s00262-012-1252-2. PMID: 22476408
  • Hardwick, N and Chain, B. Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy, June 2011, Vol 3(6): 731-33
  • Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother. 2010, 59(3):379-88.
  • Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, Barber L, Mufti GJ, Farzaneh F. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. Br J Haematol. 2009, 145(6):749-60.
  • Aloysius MM, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, Farzaneh F, Habib NA, Bhalla J, Hardwick NR, Satthaporn S, Sreenivasan T, El-Sheemy M, Eremin O. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med. 2009, 7:18
  • Ingram W, Kordasti S, Chan L, Barber LD, Tye GJ, Hardwick N, Mufti GJ, Farzaneh F. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures. Cancer Immunol Immunother. 2009, 58 (10): 1679-90
  • Denniss FA, Breslin A, Ingram W, Hardwick NR, Mufti GJ, Guinn BA. The leukaemia-associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. Br J Haematol. 2007, 138(5):668-9
  • Chan L, Hardwick NR, Guinn BA, Darling D, Gäken J, Galea-Lauri J, Ho AY, Mufti GJ, Farzaneh F. An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother. 2006, 55(8):1017-24
  • Chan L, Hardwick N, Darling D, Galea-Lauri J, Gäken J, Devereux S, Kemeny M, Mufti G, Farzaneh F. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther. 2005, 11(1):120-31. PMID: 15585413
  • Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol. 1999, 163(3):1398-408.
  • Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998, 4(5):581-7
Back To Top